AU2001264081A1 - Serine protease inhibitors - Google Patents

Serine protease inhibitors

Info

Publication number
AU2001264081A1
AU2001264081A1 AU2001264081A AU6408101A AU2001264081A1 AU 2001264081 A1 AU2001264081 A1 AU 2001264081A1 AU 2001264081 A AU2001264081 A AU 2001264081A AU 6408101 A AU6408101 A AU 6408101A AU 2001264081 A1 AU2001264081 A1 AU 2001264081A1
Authority
AU
Australia
Prior art keywords
serine protease
protease inhibitors
inhibitors
factor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264081A
Inventor
Nicholas Paul Camp
David Birenbaum Engel
Stuart Donald Jones
John Walter Liebeschuetz
John Joseph Masters
Christopher William Murray
Scott Martin Sheehan
Brian Morgan Watson
Michael Robert Wiley
William Alexander Wylie
Stephen Clinton Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/002302 external-priority patent/WO2000076971A2/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001264081A1 publication Critical patent/AU2001264081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula (I)in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.
AU2001264081A 2000-06-13 2001-06-12 Serine protease inhibitors Abandoned AU2001264081A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2000/002302 WO2000076971A2 (en) 1999-06-14 2000-06-13 Serine protease inhibitors
WOGB00/02302 2000-06-13
GB0030306 2000-12-13
GBGB0030306.5A GB0030306D0 (en) 2000-12-13 2000-12-13 Compounds
PCT/GB2001/002572 WO2001096304A1 (en) 2000-06-13 2001-06-12 Serine protease inhibitors

Publications (1)

Publication Number Publication Date
AU2001264081A1 true AU2001264081A1 (en) 2001-12-24

Family

ID=9904939

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264081A Abandoned AU2001264081A1 (en) 2000-06-13 2001-06-12 Serine protease inhibitors

Country Status (8)

Country Link
US (1) US6784182B2 (en)
EP (1) EP1289953B1 (en)
AT (1) ATE303989T1 (en)
AU (1) AU2001264081A1 (en)
DE (1) DE60113252T2 (en)
ES (1) ES2247120T3 (en)
GB (1) GB0030306D0 (en)
WO (1) WO2001096304A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7265121B2 (en) 2001-07-26 2007-09-04 Eli Lilly And Company Chemical compounds
US7294627B2 (en) 2001-12-12 2007-11-13 Eli Lilly And Company Chemical compounds
DE60336986D1 (en) 2002-03-05 2011-06-16 Sumitomo Chemical Co PROCESS FOR THE PRODUCTION OF BIARYL COMPOUNDS
PL373066A1 (en) 2002-04-01 2005-08-08 Eli Lilly And Company Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
PE20040804A1 (en) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR
AU2004244982A1 (en) * 2003-06-02 2004-12-16 Georgetown University Anti-HIV benzamide compounds
EP1628660A4 (en) * 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc Methods and compositions for modulating serum cortisol levels
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
EP2297112B1 (en) * 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
JP5667094B2 (en) 2009-03-10 2015-02-12 エムイーディー ディスカバリー エスエー Use of serine protease inhibitors in the treatment of neutropenia
KR20120087923A (en) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
CA2782384A1 (en) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
CA2200163A1 (en) 1996-03-22 1997-09-22 Michael Robert Wiley Antithrombotic diamides
AU3496297A (en) 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them
IL133625A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
EP1014962A4 (en) 1997-06-26 2007-06-27 Lilly Co Eli Antithrombotic agents
JP2002506462A (en) 1997-06-26 2002-02-26 イーライ・リリー・アンド・カンパニー Antithrombotic substance
WO1999000128A1 (en) 1997-06-26 1999-01-07 Eli Lilly And Company Antithrombotic agents
EP1012166B1 (en) 1997-08-29 2003-10-29 Tularik Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
WO2000039118A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
CA2358091A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Antithrombotic amides
WO2000039117A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa
US6660739B1 (en) 1998-12-24 2003-12-09 Eli Lilly And Company Heterocyclic amides as inhibitors of factor Xa
AU5155500A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
CA2374793A1 (en) 1999-05-24 2000-11-30 Penglie Zhang Inhibitors of factor xa
EP1192135A2 (en) * 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
EP1192132B1 (en) 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors

Also Published As

Publication number Publication date
US20020151724A1 (en) 2002-10-17
GB0030306D0 (en) 2001-01-24
EP1289953B1 (en) 2005-09-07
ES2247120T3 (en) 2006-03-01
EP1289953A1 (en) 2003-03-12
DE60113252D1 (en) 2005-10-13
WO2001096304A1 (en) 2001-12-20
DE60113252T2 (en) 2006-06-08
US6784182B2 (en) 2004-08-31
ATE303989T1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
MXPA02011411A (en) Serine protease inhibitors.
AU2001274220A1 (en) Serine protease inhibitors
AU2001264065A1 (en) Serine protease inhibitors
AU5414000A (en) Compounds
WO2000076970A3 (en) Serine protease inhibitors
AU2001264081A1 (en) Serine protease inhibitors
AU1871301A (en) Serine protease inhibitors
MXPA03005254A (en) Serine protease inhibitors.
MXPA03006224A (en) Inhibitors of cruzipain and other cysteine proteases.
SI1377574T1 (en)
SI1244643T1 (en) Tryptase inhibitors
DE60216920D1 (en) Tryptase-inhibitoren
DE60220504D1 (en) Tryptasehemmer
ATE344795T1 (en) INHIBITORS OF SERINE PROTEASES
RS20050063A (en) Pyrrolidine derivatives as tryptase inhibitors